# The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

> **NCT02414165** · PHASE2,PHASE3 · TERMINATED · sponsor: **Tocagen Inc.** · enrollment: 403 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **BIOLOGICAL:** Toca 511
- **DRUG:** Toca FC
- **DRUG:** Lomustine
- **DRUG:** Temozolomide
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT02414165
- **Lead sponsor:** Tocagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-11-30
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-12-20
- **Target enrollment:** 403 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414165, "The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02414165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*